Tyra Biosciences Narrows Loss in Q2
Tyra Biosciences (NASDAQ:TYRA), a clinical-stage biotech company focused on therapies for FGFR (fibroblast growth factor receptor) conditions, released its second quarter results on August 14, 2025. The most notable news was a net loss per share of $(0.47) (GAAP). As expected for a company without commercialized products, revenue remained at zero. Both research and development and general and administrative spending rose significantly from the previous year. Overall, the quarter reflected active clinical progress, higher expenses, and a solid cash position, but the absence of near-term revenue continues as the norm.
Source: Analyst estimates for the quarter provided by FactSet.
Tyra Biosciences specializes in developing precision medicines targeting FGFR-related diseases, with an emphasis on oncology and rare skeletal disorders. The company’s main product candidates—dabogratinib, TYRA-200, and TYRA-430—are all investigational drugs focused on various advanced cancers and genetic bone conditions. Tyra leverages its proprietary SNÅP drug design platform to accelerate new therapeutic discovery and optimize compounds for selectivity and efficacy.
Source Fool.com
